New Childhood Cancer Advocacy Group States Seven Key Aims

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

ALEXANDRIA, Virginia-More than 20 national advocacy groups, professional medical societies, and scientific organizations have joined to form the Alliance for Childhood Cancer to support quality cancer care for children and adolescents.

ALEXANDRIA, Virginia—More than 20 national advocacy groups, professional medical societies, and scientific organizations have joined to form the Alliance for Childhood Cancer to support quality cancer care for children and adolescents.

Seven core principles will guide the group’s efforts: (1) Early access to pediatric oncology specialists for evaluation, diagnosis, and treatment; (2) treatment by a multidisciplinary team of specialists; (3) insurance coverage for clinical trials; (4) access to the full continuum of care, including insurance coverage for these services; (5) portability of insurance coverage; (6) long-term follow-up care; and (7) funding to support research to improve the care and quality of life of children and adolescents, and the training of skilled pediatric cancer specialists.

Related Videos
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content